Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea

作者：Baek Chung Hee; Kim Ji Hyun; Yu Hoon; Shin Eunhye; Cho Hyungjin; Kim Hyosang; Yang Won Seok; Han Duck Jong; Park Su Kil^*

来源：Experimental and Clinical Transplantation, 2016, 14(4): 389-393.

DOI：10.6002/ect.2015.0271

• Kidney transplantation
• Tacrolimus
• Basiliximab

Objectives: Basiliximab is used alongside tacrolimusbased immunosuppression for routine induction therapy, even for well-matched living-donor renal transplant recipients. Because tacrolimus is a different drug from cyclosporine, this study examined the utility of tacrolimus-based immunosuppression without basiliximab for well-matched living-donor renal transplant recipients.
Material and Methods: This prospective study evaluated 36 patients who underwent 1 to 3 human leukocyte antigens mismatched living-donor renal transplants without basiliximab induction therapy between April 2012 and March 2015 (group 1). All transplants were ABO compatible and T-flow negative and were followed until April 2015. Tacrolimus-based triple therapy was used for maintenance immuno suppression. The control group comprised 72 age-and sex-matched patients who underwent 1 to 3 human leukocyte antigens mismatched living-donor renal transplants with basiliximab induction therapy during the same period (group 2).
Results: Two patients in group 1 and 12 patients in group 2 had infection, with cytomegalovirus infection and Pneumocystis pneumonia infection occurring only in group 2 and BK virus and urinary tract infection reported in both groups, with a similar incidence. One patient from group 2 had sepsis. Although the incidence of infection tended to be lower in group 1 than in group 2 (5.6% vs 16.7%), the overall incidence of infection was not significantly different (P =.135). In addition, there were no significant differences in incidence of acute rejection between groups 1 and 2 (2.8% vs 4.2%; P =.699). All patients showed stable renal function after treatment.
Conclusions: Tacrolimus-based triple drug maintenance immunosuppression without basiliximab might be an optimal treatment choice for individuals undergoing well-matched living-donor renal transplant.

• 出版日期2016-8